Associated Papers
Discovery and Characterization of Zilurgisertib, a Potent and Selective Inhibitor of Activin Receptor-like Kinase‑2 (ALK2) for the Treatment of Fibrodysplasia Ossificans Progressiva.
Ullrich T et al.
Acs Medicinal Chemistry Letters, 2025
Select a paper to view details